BIO Jun 2023 250.000 put
| Previous close | 10.31 |
| Open | N/A |
| Bid | 1.30 |
| Ask | 6.00 |
| Strike | 250.00 |
| Expiry date | 2023-06-16 |
| Day's range | 10.31 - 10.31 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
ZacksBio-Rad Laboratories (BIO) Gains But Lags Market: What You Should Know
In the latest trading session, Bio-Rad Laboratories (BIO) closed at $372.36, marking a +0.27% move from the previous day.
ZacksBio-Rad (BIO) Faces Macroeconomic Headwinds, Rising Expenses
Bio-Rad's (BIO) process chromatography business witnesses a slowdown in the quarter due to tough comparisons and some softness in the bioprocessing market.
Business WireBio-Rad to Present Company Overview at Jefferies Healthcare Conference
HERCULES, Calif., June 01, 2023--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, will present a company overview at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 3 PM Eastern Time. The presentation will be followed by a Q&A session with participation from Bio-Rad’s Executive Vice President and CFO Ilan Daskal.
Simply Wall St.Is It Time To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?
Today we're going to take a look at the well-established Bio-Rad Laboratories, Inc. ( NYSE:BIO ). The company's stock...
- Simply Wall St.
Bio-Rad Laboratories First Quarter 2023 Earnings: EPS: US$2.33 (vs US$112 loss in 1Q 2022)
Bio-Rad Laboratories ( NYSE:BIO ) First Quarter 2023 Results Key Financial Results Revenue: US$676.8m (down 3.3% from...
Business WireBio-Rad to Participate in Fireside Chat During 2023 RBC Capital Markets Global Healthcare Conference
HERCULES, Calif., May 08, 2023--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that the company’s management will participate in a fireside chat event during the 2023 RBC Capital Markets Global Healthcare Conference on Wednesday, May 17, 2023, at 3:35 PM Eastern Time (12:35 PM Pacific Time).
ZacksBio-Rad (BIO) Q1 Earnings Beat Estimates, Operating Margin Down
Bio-Rad's (BIO) first-quarter results reflect core strength across the Life Science and Clinical Diagnostics segments amid ongoing supply-chain constraints.
ZacksBio-Rad Laboratories (BIO) Q1 Earnings and Revenues Beat Estimates
Bio-Rad (BIO) delivered earnings and revenue surprises of 3.09% and 0.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Business WireBio-Rad Reports First-Quarter 2023 Financial Results
HERCULES, Calif., May 04, 2023--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2023.
ZacksHere's Why You Should Retain Exact Sciences (EXAS) Stock Now
Investors are optimistic about Exact Sciences (EXAS) on continued strength across the Screening and Precision Oncology businesses.
ZacksEmbecta (EMBC) to Report Q2 Earnings: What's in Store?
Embecta's (EMBC) diabetes care business is expected to have progressed in the fiscal second quarter banking on strong execution of its three strategic pillars.
- Zacks
Charles River (CRL) to Report Q1 Earnings: What's in Store?
Continued global demand for research models and associated services are likely to have driven Charles River's (CRL) Q1 revenues.
ZacksAre Medical Stocks Lagging BioRad Laboratories (BIO) This Year?
Here is how Bio-Rad Laboratories (BIO) and GSK (GSK) have performed compared to their sector so far this year.
ZacksAlcon (ALC) to Report Q1 Earnings: What's in the Cards?
Amid persistent supply-chain headwinds, Alcon's (ALC) first-quarter top-line results are likely to reflect the commercial execution of new product launches across its segments and contributions from strategic alliances.
ZacksWhat's in Store for DENTSPLY SIRONA (XRAY) in Q1 Earnings?
DENTSPLY SIRONA's (XRAY) first-quarter 2023 results are likely to reflect strong performance in the Technologies & Equipment business.
ZacksQuest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down
Quest Diagnostics (DGX) base business registers growth in the first quarter of 2023.
- Zacks
Integra's (IART) Q1 Earnings Match Estimates, Margins Contract
In CSS, Integra (IART) witnesses a good start to the year with double-digit growth in the CUSA product line and programmable valves as well as strong performance in instrument sales.
ZacksBio-Rad Laboratories (BIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Bio-Rad (BIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksEdwards Lifesciences (EW) Q1 Earnings Top Estimates, '23 View Up
Edwards Lifesciences (EW) continues to register strong momentum in TMTT, led by the continued adoption of the PASCAL Precision system in Europe.
ZacksLamb Weston and TTEC Holdings have been highlighted as Zacks Bull and Bear of the Day
Lamb Weston and TTEC Holdings have been highlighted as Zacks Bull and Bear of the Day.
ZacksThe Zacks Analyst Blog Highlights BioRad Laboratories, Henry Schein, Insulet, Abbott and LabCorp
BioRad Laboratories, Henry Schein, Insulet, Abbott and LabCorp are included in this Analyst Blog.
ZacksBoston Scientific (BSX) Q1 Earnings Beat, 2023 View Raised
Reported and organic revenues at each of Boston Scientific's (BSX) core business segments and geographies increase in the reported quarter.
ZacksThermo Fisher (TMO) Q1 Earnings Beat Estimates, Margins Down
The year-over-year growth in the Analytical Instruments and the Laboratory Products and Biopharma Services segments drove Thermo Fisher's (TMO) Q1 revenues.
Zacks3 MedTech Stocks Likely to Beat Estimates in Q1 Earnings
MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how BIO, HSIC and PODD are poised ahead of their earnings releases.
ZacksLabCorp (LH) Q1 Earnings Miss Estimates, Margins Decline
The decline in COVID-19 PCR and antibody testing sales, the severe foreign exchange headwind and inflationary pressure hurt LabCorp's (LH) business performance in Q1.
